☆ 4.4 Article

BIO89-100, a GlycoPEGylated FGF21 Analog, Improved Serum Lipids and Extended Half-Life in a Controlled Single Ascending Dose Trial in Healthy Subjects†

Journal of Clinical Lipidology (2020)

Get Full Text
Add to Collection

Journal

Journal of Clinical Lipidology
Volume 14, Issue 4, Pages 585-586

Publisher

Elsevier BV
DOI: 10.1016/j.jacl.2020.05.067

Keywords

-

Categories

Pharmacology & Pharmacy

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.